Tania Jain, MBBS, discusses the role of ruxolitinib as treatment of graft-versus-host disease.
Tania Jain, MBBS, assistant professor at Johns Hopkins University, discusses the role of ruxolitinib (Jakafi) as treatment of graft-versus-host disease (GVHD).
At her institution, she has used ruxolitinib as treatment of GVHD for patients with grade 2 through 4 disease. However, because of the biology of GVHD, responses are observed more frequently in patients with grade 2 versus grades 3 and 4 GVHD. This is consistent with data that has been observed in the REACH-1 and REACH-2 clinical trials.
Although there are responses with ruxolitinib, physicians should be wary of potential infections or cytopenias, Jain says. Physicians should keep these concerns in mind as they use the agent.
Prior Pelvic Radiation Linked to Higher Complications After Bladder Cancer Surgery
April 30th 2025Bladder cancer patients undergoing radical cystectomy after pelvic radiotherapy showed increased risks of rectal injury, readmission, sepsis, and surgical-site infections compared with primary surgery.
Read More
Radical Prostatectomy Shows Less Genitourinary Toxicity in Localized Prostate Cancer
April 30th 2025A study of 47,387 patients found radical prostatectomy had the lowest long-term risk of severe genitourinary complications after localized prostate cancer treatment compared to combination therapies.
Read More